Abstract
We identified constitutional truncating mutations of the BRCA1-interacting helicase BRIP1 in 9/1,212 individuals with breast cancer from BRCA1/BRCA2 mutation–negative families but in only 2/2,081 controls (P = 0.0030), and we estimate that BRIP1 mutations confer a relative risk of breast cancer of 2.0 (95% confidence interval = 1.2–3.2, P = 0.012). Biallelic BRIP1 mutations were recently shown to cause Fanconi anemia complementation group J. Thus, inactivating truncating mutations of BRIP1, similar to those in BRCA2, cause Fanconi anemia in biallelic carriers and confer susceptibility to breast cancer in monoallelic carriers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis
World Journal of Surgical Oncology Open Access 13 March 2023
-
Breast cancer in the era of integrating “Omics” approaches
Oncogenesis Open Access 14 April 2022
-
Comprehensive germline-genomic and clinical profiling in 160 unselected children and adolescents with cancer
European Journal of Human Genetics Open Access 12 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Antoniou, A.C. & Easton, D.F. Genet. Epidemiol. 21, 1–18 (2001).
Cantor, S.B. et al. Cell 105, 149–160 (2001).
Cantor, S. et al. Proc. Natl. Acad. Sci. USA 101, 2357–2362 (2004).
Peng, M. et al. Oncogene 25, 2245–2253 (2006).
Cantor, S.B. & Andreassen, P.R. Cell Cycle 5, 164–167 (2006).
Meijers-Heijboer, H. et al. Nat. Genet. 31, 55–59 (2002).
Renwick, A. et al. Nat. Genet. 38, 873–875 (2006).
Levitus, M. et al. Nat. Genet. 37, 934–935 (2005).
Levran, O. et al. Nat. Genet. 37, 931–933 (2005).
Litman, R. et al. Cancer Cell 8, 255–265 (2005).
Howlett, N.G. et al. Science 297, 606–609 (2002).
Taniguchi, T. & D'Andrea, A.D. Blood 107, 4223–4233 (2006).
Swift, M. et al. J. Natl. Cancer Inst. 65, 863–867 (1980).
Seal, S. et al. Cancer Res. 63, 8596–8599 (2003).
Reid, S. et al. J. Med. Genet. 42, 147–151 (2005).
Acknowledgements
We thank the participating families who were recruited to the study by the Familial Breast Cancer Collaboration (UK), which includes the following contributors: A. Ardern-Jones, J. Berg, A. Brady, N. Bradshaw, C. Brewer, G. Brice, B. Bullman, J. Campbell, B. Castle, R. Cetnarsryj, C. Chapman, C. Chu, N. Coates, T. Cole, R. Davidson, A. Donaldson, H. Dorkins, F. Douglas, D. Eccles, R. Eeles, F. Elmslie, D.G. Evans, S. Goff, S. Goodman, D. Goudie, J. Gray, L. Greenhalgh, H. Gregory, N. Haites, S.V. Hodgson, T. Homfray, R.S. Houlston, L. Izatt, L. Jeffers, V. Johnson-Roffey, F. Kavalier, C. Kirk, F. Lalloo, I. Locke, M. Longmuir, J. Mackay, A. Magee, S. Mansour, Z. Miedzybrodzka, J. Miller, P. Morrison, V. Murday, J. Paterson, M. Porteous, N. Rahman, M. Rogers, S. Rowe, S. Shanley, A. Saggar, G. Scott, L. Side, L. Snadden, M. Steel, M. Thomas and S. Thomas. We thank A. Hall and E. Mackie for coordination of sample collection. We are grateful for the support of the Daniel Faulkner Trust and the Geoffrey Berger Charitable Trust. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. P. Kelly is supported by a grant from the Breast Cancer Campaign. M.A., B.N. and A.E. are supported by US Army Medical Research and Material Command grant #W81XWH-05-1-0204. This research was supported by the Institute of Cancer Research and Cancer Research UK.
Author information
Authors and Affiliations
Consortia
Contributions
The study was designed by N.R. and M.R.S. The molecular analyses were performed by S.S., A.R., P.K., R.B., T.C., H.J., M.A. and K.S. under the direction of N.R. The statistical analyses were performed by D.T., A.E., B.N. and L.M. under the direction of D.F.E. The familial collections were initiated by G.E. and D.E. and were collected by the Breast Cancer Susceptibility Collaboration (UK). The manuscript was written by N.R. and M.R.S.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Primers and PCR conditions for BRIP1 coding exons. (PDF 9 kb)
Supplementary Table 2
Nonsynonymous BRIP1 missense variants in breast cancer cases and controls. (PDF 8 kb)
Rights and permissions
About this article
Cite this article
Seal, S., Thompson, D., Renwick, A. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38, 1239–1241 (2006). https://doi.org/10.1038/ng1902
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1902
This article is cited by
-
Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis
World Journal of Surgical Oncology (2023)
-
Breast cancer in the era of integrating “Omics” approaches
Oncogenesis (2022)
-
Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma
Clinical Journal of Gastroenterology (2022)
-
Comprehensive germline-genomic and clinical profiling in 160 unselected children and adolescents with cancer
European Journal of Human Genetics (2021)
-
Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk
Current Treatment Options in Oncology (2021)
